ArticleEmerging microbes & infections2026
SFTSV-encoded microRNA-like small RNA as prognostic biomarkers in severe fever with thrombocytopenia syndrome.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is a highly fatal infectious disease caused by the SFTS virus (SFTSV). Reliable prognostic biomarkers are essential for early intervention, yet specific markers for SFTSV infection remain unidentified. In this study, we identified SFTSV-encoded microRNA-like small RNAs (milRNAs) in patients' sera and evaluated their potential as prognosis biomarker. A multi-phase study involving 170 laboratory-confirmed SFTS patients, 40 patients with other infection and 80 healthy controls was conducted. Small RNA deep sequencing was performed, followed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and TA cloning for individual validation. The expression dynamics of identified milRNAs were analyzed across different disease stages, and their prognostic potential was assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression. Three SFTSV-encoded milRNAs - SFTSV-S-1480 (S-1480), SFTSV-M-692 (M-692), and SFTSV-L-4706 (L-4706) - were significantly elevated in the sera of severe patients but were nearly undetectable in mild cases and healthy controls. Their expression levels increased notably during the multiple organ dysfunction (MOD) stage, correlating with disease progression. Patients with higher milRNA expression had significantly shorter survival compared to those with lower expression. Receiver operating characteristic (ROC) curve analysis demonstrated that the three-milRNA panel outperformed traditional blood immune cell indicators in predicting disease severity. Our study identifies a panel of three SFTSV-encoded milRNAs as novel prognostic biomarkers for SFTS. Their strong correlation with disease progression and clinical outcomes suggests their potential utility for early risk stratification and targeted intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.